Insider buying
~$1.3K700 sh @ $1.89
Traded May 22, 2025 · filed the same day
The CEO of Biocardia paid $1.3K out of pocket for Biocardia shares. 5 other people at Biocardia bought some too, in the same month.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Apr 23, 2025 · Filed Apr 26, 2025
The CEO of Biocardia paid $50K out of pocket for Biocardia shares. 5 other people at Biocardia bought some too, in the same month. Shares held went up 23% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$49,999
Shares × reported transaction price
$25K–$100K
+23.3%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 15 earlier confirmed purchases
6 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 10% of the CEO's reported total pay for fiscal 2024 ($493K)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2025-11-03. The proxy names Peter Altman as CEO for that year. A size comparison, not a judgement
28 days after results of Mar 26, 2025, 21 days before results of May 14, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.3% | +2.3% | +1.0% |
| 30 days | −12.8% | +6.7% | −19.5% |
| 90 days | −5.4% | +15.6% | −21.0% |
| 180 days | −45.9% | +24.4% | −70.3% |
| 365 days | −52.9% | +29.2% | −82.1% |
Past results only. Not a forecast.
Insider buying
Traded May 22, 2025 · filed the same day
The CEO of Biocardia paid $1.3K out of pocket for Biocardia shares. 5 other people at Biocardia bought some too, in the same month.
Insider buying
Traded May 20, 2025 · filed 2 days later
The CEO of Biocardia paid $3.3K out of pocket for Biocardia shares. 5 other people at Biocardia bought some too, in the same month.
Insider buying
Traded May 16, 2025 · filed the same day
The CEO of Biocardia paid $730 out of pocket for Biocardia shares. 5 other people at Biocardia bought some too, in the same month.
Peter Altman, President and CEO's past purchases, 90 days after disclosure: 38 buys, median −9.0 pts vs S&P 500, beat it 13 of 38 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.